Completed PHASE3 INTERVENTIONAL NCT00251992

Nexium Dyspepsia/AST

Supportive Test for Acid-Related Symptoms (STARS II) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Uninvestigated Subjects With Upper Gastrointestinal Symptoms.

Sponsor: AstraZeneca

Conditions Dyspepsia Gastrointestinal Disease Signs and Symptoms, Digestive

Interventions Esomeprazole

Updated 7 times since 2017 Last updated: Jan 21, 2011 Started: Dec 31, 2002 Primary completion: Jan 31, 2005 Completion: Jan 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Dyspepsia and Gastrointestinal Disease, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Ajax, Canada , Angers, France , Ans, Belgium , Audley, United Kingdom , Bay Roberts, Canada , Bekkestua, Norway , Bergen, Norway , Blackburn, United Kingdom , Blackpool, United Kingdom and 171 more locations